What is Accellix?
Accellix is a biotechnology company dedicated to developing and commercializing the Accellix Platform. This proprietary technology is designed to empower customers in the cell and gene therapy field to meet stringent quality control (QC) requirements as they advance life-changing therapies. The Accellix platform facilitates the migration of existing cell assays, offering a benchtop flow cytometer that operates with capillary cartridges integrated with dry reagents. It is engineered to provide exceptional reproducibility and ease of use for automated, multi-parametric cell analysis, thereby streamlining critical processes for biopharmaceutical development.
How much funding has Accellix raised?
Accellix has raised a total of $19.6M across 3 funding rounds:
Debt
$150K
Series D
$9.5M
Private Equity
$10M
Debt (2020): $150K with participation from PPP
Series D (2020): $9.5M led by bioMérieux SA
Private Equity (2021): $10M supported by BroadOak Capital Partners
Key Investors in Accellix
BroadOak Capital Partners
BroadOak Capital Partners is a boutique financial institution specializing in direct investment and banking services for life sciences and biopharma services companies. Since its inception in 2006, it has invested in over 70 companies and advised on more than 50 successful M&A transactions. The firm focuses on life sciences tools, diagnostics, and biopharma services, leveraging its in-house expertise and extensive networks to deliver exceptional results for its clients. BroadOak aims to provide growth capital and advisory services to help management teams optimize their business strategies.
PPP
Public-Private Partnership
bioMérieux SA
Undisclosed investor participating in the funding round.
What's next for Accellix?
With the recent infusion of major strategic investment, Accellix is poised for accelerated growth and platform expansion. The company's focus on enabling cell and gene therapy developers to meet QC demands positions it at a crucial juncture in the biopharmaceutical value chain. Future endeavors will likely involve scaling operations, enhancing the Accellix Platform's capabilities, and forging deeper partnerships within the life sciences and biopharma services industries. This strategic financing is expected to fuel further innovation and market penetration, solidifying Accellix's role in supporting the advancement of novel therapeutic modalities.
See full Accellix company page
